Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new safety signals in patients with previously treated <i>KRAS</i> p.G12C-mutated NSCLC. (Fund...
Publications
View AllInstitution Info
- Type
- healthcare
- Country
- GB
- Publications
- 1
- Citations
- 1,567
External Links
Identifiers
- ROR
- https://ror.org/050j7sq19